← Back to headlines
Chardan Maintains Buy Rating on Iovance Biotherapeutics (IOVA)
Chardan, a financial firm, has maintained its "Buy" rating on Iovance Biotherapeutics (IOVA) stock.
Sources
Showing 0 of 1 sources
No articles available in your preferred languages.
1 article available in other languages below.
